Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

2026-03-06 - 23:17

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion. SURESNES, France and BRISBANE, Calif., March 7, 2026 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, and